抗体蛋白纯度变化与工艺相关性:各单元工序蛋白应力技术综述
抗体蛋白的纯度变化与工艺的相关性
文章按原液解冻、搅拌混合、除菌过滤、灌装、冻干与目检包装等工序,梳理抗体蛋白聚集和亚可见颗粒的应力来源及对应检测指标。文中引用 ISPE 关于气-液界面应作为工艺参数的观点,以及泵型研究中 SEC 结果不变而亚可见颗粒明显增加的数据。作者建议在各工序留取过程样并检测 SEC、MFI、PS 含量与浓度,以便把异常定位到工序级。
抗体制剂生产过程中,蛋白承受的应力包括:界面(气-液、冰-液、固-液)、剪切、冻融、冷冻浓缩、干燥、光照、氧化、包材浸出物。Biopharm International 的综述开篇提到:
"Biopharmaceutical product manufacturing is a complex process that involves many steps, including drug substance and bulk formulation, filtration, shipping, pooling, filling, lyophilization, inspections, packaging, and storage. During these processes, proteins are subjected to many different forms of stresses, such as agitation, temperature, light exposure, and oxidation. These stresses can lead to protein denaturation and aggregation."(Stress and Protein Instability During Formulation and Fill/Finish Processes, Biopharm International)
而分子层面的"敏感点"包括:界面吸附倾向(疏水斑块)、冻融敏感性(冷变性、缓冲液 pH 位移敏感)、CDR 区脱酰胺易感 Asn、易氧化 Met/Trp、铰链区断裂敏感性。
一、原液解冻:冰-液界面与冷冻浓缩是主敌
冻存原液融化的过程中,蛋白经历冰晶机械挤压、冷冻浓缩(盐、蛋白浓度数倍升高、缓冲盐结晶导致 pH 位移)、以及冰-液界面吸附。最新研究(Eur J Pharm Biopharm, 2025)甚至证实剪切并非来自泵,而是来自冰相渗透:
"Cold denaturation was evidenced as an important contributing factor in protein aggregation during freeze–thaw... Aggregation increased when ice enclosed large liquid domains, generating higher pressure-induced mechanical stresses... suggesting the contribution of shear stress from ice interface percolation."(Deciphering protein aggregation in freeze-thaw process: the roles of cold denaturation and shear stress)
冷冻浓缩与 pH 位移的经典机制描述:
"The concentration of solutes (salt, excipient, antibodies, etc.) may increase several folds due to liquid–liquid phase separation and partitioning of unfrozen solutes, generating crystallization or precipitation, or pH change and finally impair the protein stability... as ice forms, the protein can directly interact with the ice surface, which disturbs the native structure of the antibody and causes protein denaturation."(Developability assessment at early-stage discovery…, Antibody Therapeutics, 2022)
SEC HMW增加、亚可见颗粒增加(解冻后立即出现) :冰-液界面吸附聚集、冷变性,配方保护不足(PS80/蔗糖缺乏)
icIEF/AEX 酸性峰增加(伴随颗粒增多) :冻融伴随的氧化与界面变性,含苯甲醇处方研究证实冻融同时推高聚集体与酸性变异体
主峰不变、CE-SDS 不变,仅颗粒增加:界面应力产生的是亚可见/不可溶颗粒,SEC 检不出,不能只看 SEC
苯甲醇与冻融的协同破坏(Int J Pharm, 2025):
"These combined effects increased subvisible particles, soluble aggregates, and acidic variants... including interfacial exposure, shear forces from concentration gradients, and methionine oxidation due to increased dissolved oxygen."(Benzyl alcohol exacerbates freeze–thaw-induced aggregation of trastuzumab)
冻融敏感性是分子特异性的:"Some proteins are prone to freeze/thaw stress, and the process results in protein aggregation, while others are much more resistant. Studies have shown that freeze/thaw-induced protein aggregation is mainly attributed to interfacial adsorption of protein at ice-liquid interfaces."(Biopharm International)。开发阶段应做冻融循环筛选(如 −80°C 冻、2–8°C 融),并在批记录中明确解冻速率与化冻方式。文献指出冰相包裹未融液滴的几何形态(瓶装、自底向上冻结)会显著加剧聚集。
二、搅拌混合:真正的风险是气-液界面,不是桨叶
这是最容易被误解的点,ISPE 的文章标题就叫《气-液界面是一个工艺参数》:
"Proteins are surface active. At an air-water interface a monoclonal antibody adsorbs and then partly unfolds, because its hydrophobic core is more comfortable facing air than facing water. Disturb that film and the unfolded molecules return to the bulk, where they act as nuclei for aggregation. Every time the surface is renewed a fresh interface is made and the cycle is run again: a vortex folding air down, a splash, a stream falling from an addition port into the bulk below."(The Air-Liquid Interface Is a Process Parameter, ISPE Pharmaceutical Engineering)
作者进一步强调剪切本身在工业剪切率下不足以破坏蛋白:
"Two concentrated IgG1 formulations were once held at shear rates between 20,000 and 250,000 per second, far above anything a compounding impeller generates, and shear alone did not cause aggregation. The same authors put the force available at an air-water interface at roughly 140 piconewtons, against the 20 to 150 piconewtons needed to unfold a protein, and concluded that air-bubble entrainment and adsorption to surfaces matter far more in production than shear does."
搅拌应力下通常只出现轻度变化,且聚集体与电荷变异体同步微升:
"After subjecting the samples to 400 rpm agitation for 24 h and 72 h... the monomer level decreased by 0.63%... while the aggregate level increased by 0.69%... After 24 and 72 h of agitation stress, a slight decrease was observed in the main charge variants, while an increase was observed in the acidic and basic charge variants."(Comparative Forced Degradation Study of Anticomplement C5 Biosimilar and Originator Monoclonal Antibodies*, Pharmaceutics, 2025)
亚可见颗粒增多、SEC HMW增加:搅拌体积低或涡流可见 ,气-液界面卷入(涡流、飞溅、加料口冲击)
同一配方放大后颗粒系统性偏高、无 assignable cause:放大未保持界面条件,别只看转速
蛋白浓度高的批次更稳,浓度效应对搅拌聚集有保护作用:"Increase in protein concentration also is reported to decrease aggregation with respect to agitation"(Biopharm International)
"Polysorbate, a nonionic surfactant, accumulates at the air–liquid interface and is therefore widely used in mAb formulations to prevent mechanically induced aggregation."(Pharmaceutics, 2025)
聚山梨酯的保护机制是"抢先占界面"的竞争吸附。若处方 surfactant 不足、或 PS 被滤膜吸附消耗,同样的搅拌操作就可能从"无异常"变成"颗粒超标"。此外要关注涡流深度、最小桨叶浸没深度。
三、除菌过滤:吸附损失 + 聚集
滤膜巨大的表面积 + 泵送压力/剪切。两类风险:蛋白损失与聚集/颗粒诱发。膜材差异巨大:
"CA and PES membranes performed best, with average adsorption of less than 5%... Nylon and PVDF membranes showed over 30% adsorption... A study on filtering low-concentration therapeutic mAbs through PVDF membranes observed the loss of high molecular weight species (HMWS) during sterile filtration."(Sartorius DoE )
吸附呈浓度依赖,低浓度/小体积时风险最大:
"For mAb P2G12, when the concentration was below 1.0 g/L, the post-filtration product concentration decreased significantly compared to the standard protocol, and the protein adsorption behavior could be well described by a Langmuir adsorption isotherm."
聚集风险也不容忽视:
"Protein in the filtration process is subject to shear stress, interfacial exposure and pH changes, and may undergo conformational changes and even aggregation. Particles shed from the membrane surface may even act as 'seeds' for aggregation."
过滤前后蛋白浓度偏低: 膜吸附(换 CA/PES 膜)或系统持液量(holdup volume)过大 |
过滤后 HMW 反而略降 : 聚集体被滤膜截留"aggregate removal",这可能掩盖处方不稳定的问题
过滤端出现新亚可见颗粒: 膜脱落颗粒异相成核、界面/剪切暴露,或泵选型问题
surfactant 含量下降 : PS 被膜吸附,后续工序界面保护被"抽空",务必检测滤后 PS 含量
Pharm Tech 的行业综述确认了这一组合风险:
"Factors related specifically to sterile filtration that can impact the final formulation include the contact surfaces, shear forces involved, and the potential to induce aggregation or particle formation... The adsorption of components of the final formulations and the biologic drug substance to the sterile filter must be analyzed to ensure that the formulation and final concentrations remain within the desired values."(Considerations for Sterile Filtration of Biologic Drugs)
疏水斑块暴露多、pI 偏中性(静电吸附强)、低浓度制剂最敏感。此外含 Met 残基的分子要警惕去污/灭菌化学残留的氧化:抗体结合区 Met 被(如 VHP 灭菌残留的)氧化可"lose efficacy"。
四、灌装:泵型选择是质量属性问题,不只是精度问题
"Filling processes can impact product quality by introducing physical stresses such as shear, friction, and cavitation. Other detrimental factors include temperature generated in the process of filling, foaming, and contact with filling system materials, including processing aids such as silicone oil. Certain pumps may shed extrinsic particles that may lead to heterogeneous nucleation-induced aggregation."(Nayak et al., Characterization of Subvisible Particle Formation During the Filling Pump Operation of a Monoclonal Antibody Solution*, J Pharm Sci, 2011)
Roche 团队用 CFD + 脂质体剪切模型揭示了旋转柱塞泵的"累积剪切"机制:
"The rotary piston pump creates a recirculation zone inside the cylinder, where the protein formulation could be trapped and be exposed to the shear stress multiple times resulting in a cumulative shearing. This finding could serve as an explanation for the highest sub-particle counts in low volume filling using a rotary piston pump."(Dreckmann et al., Eur J Pharm Biopharm, 2019, PMID 31837391)
关键案例:SEC 不变,颗粒暴涨
Nayak 的经典研究是最重要的"指标映射"教材:将制剂经泵循环最多 20 次(加速条件),
"All samples had monomer of 99.4% and dimer of 0.6%. No change in percentage of monomer or percentage of dimer was detected by SEC... The rolling diaphragm pump, peristaltic pump, and time–pressure filler generated notably less protein subvisible particles than the rotary piston pump... An extreme increase in subvisible particles was also reflected in an increase in turbidity."(J Pharm Sci, 2011)
SEC 完全正常、icIEF/CE-SDS 正常,但 MFI 亚可见颗粒增加、浊度增加、目检剔除率增加: 泵型(旋转柱塞泵)、不锈钢纳米颗粒异相成核(Tyagi et al., 2009)、硅油微滴、气穴
不同批次间颗粒差异大但均在限内: 泵转速/背压/针头规格变化导致的界面与剪切差异(Sediq et al.: 工业级剪切本身不足以使蛋白在主体溶液中变性)
高浓度、高粘度制剂对泵型最敏感(所需压力更高、接触时间更长);对不锈钢颗粒"成核"敏感的分子(带正电区域与钢表面负电吸引)更需排查金属接触面。
五、冻干:应力集中在"冻",风险潜伏在"存"
工序应力:冷冻浓缩、pH 位移、界面、干燥
"During freezing, crystallisation of ice leads to an increase in solute concentration remaining in the unfrozen phase... As the concentration of charged solute goes up during concentration, ionic strength increases eventually leading to charge shielding and enhanced attractive protein self-interaction... a pH shift of the system as a function of temperature, in extreme cases drastically enhanced by preferential crystallisation of buffer components can alter protein stability. Phosphate buffers may show a downward shift of up to 4 pH units."(Freeze concentration during freezing: How does the maximally freeze concentrated solution influence protein stability?, Int J Pharm, 2020)
干燥脱水的破坏机制:
"Throughout the FD process, the removal of water molecules disrupts the original hydrogen bonds between proteins and water, which may lead to protein inactivation unless appropriate formulation strategies are adopted."(Gao et al.,转引自冻干稳定剂综述)
赋形剂结晶是常被忽视的环节:
"PS promoted sucrose crystallization in both low concentration antibody studies during storage."(Does controlled nucleation impact the properties and stability of lyophilized monoclonal antibody formulations?, Eur J Pharm Biopharm, 2018——含聚山梨酯处方的蔗糖在储存期结晶,意味着界面保护与玻璃态骨架同时失效)
冻干后 SEC HMW增加(成品 vs 半成品对照): 冰-液界面/冷冻浓缩损伤,检查 PS 含量、Tg′ 余量、退火条件
粉饼储存期间酸峰增加、HMW增加: 残余水分偏高加速固相脱酰胺/氧化,或赋形剂结晶(蔗糖结晶、甘露醇失稳) |
崩塌/皱纹饼 + 聚集增加: 一次干燥品温超 Tc,玻璃态软化截留水汽
批间残余水分离散: 控制成核一致性
复溶后颗粒增加: 饼体崩塌、复溶操作粗暴
残余水分的窗口效应(非越干越好):
"Chang et al. found that optimal stability of the pure IgG1 antibody was at a water content of 2%–3%. The lowest water content is not necessarily the optimal condition."(Antibody Storage and Antibody Shelf Life, Methods Mol Biol)
对 pH 位移敏感(磷酸缓冲液慎用)、界面敏感(必须 PS 保护)、固相化学降解快慢取决于玻璃态分子流动性。
"Protein integrity in the FC was not affected by 1 month storage at temperatures above Tg'. Thus, upconcentration of solutes during freezing does not negatively impact protein stability."
真正的伤害来自界面与干燥脱水,这决定了工艺改进的着力点。
六、目检与包装:包材浸出物与光照是"隐形工序"
1. 硅油(预灌封/注射器润滑):"silicone oil alone or in combination with stresses like agitation or shaking can lead to protein aggregation... studies have demonstrated that the level of aggregation is proportional to the amount of silicone oil present."(*Silicone Oil-Free Polymer Syringes for the Storage of Therapeutic Proteins*, J Pharm Sci, 2018;ONdrugDelivery, 2016)
2. 钨残留(预灌封针筒成型针残留):"Soluble tungsten residue was determined to be the root cause of unusually high levels of aggregation in clinical trial batches of epoetin alfa."(ONdrugDelivery, 2016)
3. 玻璃脱片:"Glass vials have been known to delaminate at higher pH and with citrate formulations, potentially creating protein-coated glass particles, which may enhance immunogenicity."(FDA Immunogenicity Assessment for Therapeutic Protein Products, 2014 Guidance)
4. 光照:"Light was shown to induce conversion of Trp to Gly and Gly hydroperoxide in IgG1... detergents like Tween 80 in antibody solutions may introduce additional photosensitivity."(Methods Mol Biol)
FDA 指南对包材-蛋白相互作用的总结:
"Interactions between therapeutic protein products and the container closure may negatively affect product quality and immunogenicity... Glass and air interfaces can denature proteins and cause aggregation in glass syringes and vials. Silicone oil-coated syringe components provide a chemical and structural environment on which proteins can denature and aggregate... tungsten oxide that leached from the syringe barrel was reported to cause protein aggregation."
目检剔除率异常高、MFI 颗粒增加、SEC HMW增加(成品阶段才出现): 硅油微滴与蛋白颗粒混合物,("SbVP levels by MFI in the XSi™ syringes were below 5% of the levels measured in regular siliconized syringes")
放置后浊度增加、氧化峰增加(RP-HPLC/肽图 Met 氧化) :钨浸出、顶空氧气、透氧包材
贮存后酸峰增加、伴随脱片微粒: 玻璃脱片,pH≥8、柠檬酸盐/磷酸盐处方是已识别风险因子
光稳定性考察 HMW/氧化增加: 遮光包装不足,PS 降解产物(游离脂肪酸颗粒)本身也会贡献颗粒
对金属离子敏感(钨氧化聚集案例即分子特性+包材耦合)、CDR 含 Met/Trp 者氧化即失活、酸性处方/高 pH 处方对玻璃的侵蚀有差异。运输环节(目检后的最后应力源)也应纳入:"shipping studies and in-use stability studies subject the formulation to thermal and mechanical stresses whose effect on aggregation is formulation-dependent."(FastFormulator)
结语:三条实操建
1. 每道工序留过程样:解冻后、混合后、过滤后、灌装前/后分别取样测 SEC + MFI + PS 含量 + 浓度,异常才能定位到工序级。只测 SEC 会漏掉几乎所有泵相关质量事件。
2. 把界面当工艺参数管起来:涡流深度、最小浸没深度、加料方式、滤膜/包材的蛋白与 PS 吸附。
3. 用分子特性预判敏感性:开发早期用冻融循环、振荡、泵循环三个小型应力模型把"这个分子怕什么"摸清楚,生产端的工艺参数才能有的放矢。
主要参考文献:
1. Nayak A, Colandene J, Bradford V, Perkins M. *Characterization of Subvisible Particle Formation During the Filling Pump Operation of a Monoclonal Antibody Solution.* J Pharm Sci, 2011, 100:4198–4204. PMID 21698601
2. Dreckmann T, et al. *Low volume aseptic filling: Impact of pump systems on shear stress.* Eur J Pharm Biopharm, 2019. PMID 31837391
3. *Deciphering protein aggregation in freeze-thaw process: the roles of cold denaturation and shear stress.* Eur J Pharm Biopharm, 2025.
4. *Benzyl alcohol exacerbates freeze–thaw-induced aggregation of trastuzumab: elucidating mechanisms and formulation implications for clinical practice.* Int J Pharm, 2025.
5. *Developability assessment at early-stage discovery to enable development of antibody-derived therapeutics.* Antibody Therapeutics, 2022, 6(1):13.
6. *The Air-Liquid Interface Is a Process Parameter.* ISPE Pharmaceutical Engineering.
7. *Comparative Forced Degradation Study of Anticomplement C5 Biosimilar and Originator Monoclonal Antibodies.* Pharmaceutics, 2025, 18(4):579.
8. *Considerations for Sterile Filtration of Biologic Drugs.* Pharmaceutical Technology.
9. *Freeze concentration during freezing: How does the maximally freeze concentrated solution influence protein stability?* Int J Pharm, 2020.
10. *Does controlled nucleation impact the properties and stability of lyophilized monoclonal antibody formulations?* Eur J Pharm Biopharm, 2018.
11. Werner BP, Schöneich C, Winter G. *Silicone Oil-Free Polymer Syringes for the Storage of Therapeutic Proteins.* J Pharm Sci, 2018.
12. *Cross-Linked Silicone Coating: A Novel Prefilled Syringe Technology That Reduces Subvisible Particles...* J Pharm Sci, 2015.
13. FDA Guidance for Industry: *Immunogenicity Assessment for Therapeutic Protein Products*, 2014.
14. Saffell-Clemmer W. *A Risk Management Approach to Prefilled Syringe Selection for Biotechnology Products.* ONdrugDelivery, 2016.
15. *Stress and Protein Instability During Formulation and Fill/Finish Processes.* Biopharm International.
16. *Antibody Storage and Antibody Shelf Life.* Methods Mol Biol / doi:10.13070/mm.en.2.120
来源:做药的那些个事 · mp.weixin.qq.com